Avinza is a drug owned by King Pharmaceuticals Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 25, 2017. Details of Avinza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6066339 | Oral morphine multiparticulate formulation |
Nov, 2017
(7 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Avinza is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Avinza's family patents as well as insights into ongoing legal events on those patents.
Avinza's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Avinza's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 25, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Avinza Generic API suppliers:
Morphine Sulfate is the generic name for the brand Avinza. 32 different companies have already filed for the generic of Avinza, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Avinza's generic
How can I launch a generic of Avinza before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Avinza's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Avinza's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Avinza -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 30 mg, 60 mg, 90 mg and 120 mg | 04 Jun, 2007 | 1 | 16 Jan, 2013 | 25 Nov, 2017 | Deferred |
| 45 mg and 75 mg | 11 Aug, 2009 | 1 | 25 Nov, 2017 | Extinguished |
Alternative Brands for Avinza
There are several other brand drugs using the same active ingredient (Morphine Sulfate) as Avinza. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Alpharma Pharms |
| |
| Fresenius Kabi Usa |
| |
| Ohemo Life |
| |
| Pacira Pharms Inc |
| |
| Zyla |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Morphine Sulfate, Avinza's active ingredient. Check the complete list of approved generic manufacturers for Avinza
About Avinza
Avinza is a drug owned by King Pharmaceuticals Llc. Avinza uses Morphine Sulfate as an active ingredient. Avinza was launched by King Pharms Llc in 2002.
Approval Date:
Avinza was approved by FDA for market use on 20 March, 2002.
Active Ingredient:
Avinza uses Morphine Sulfate as the active ingredient. Check out other Drugs and Companies using Morphine Sulfate ingredient
Dosage:
Avinza is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 75MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 45MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 60MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 120MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 30MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 90MG | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |